Incyte reveals promising results for Monjuvi trial
WILMINGTON — Incyte has announced promising results from a third phase of a trial studying Monjuvi, including more than half of the patients in the drug study showing meaningful improvement in follicular lymphoma. Monjuvi, also known as tafasitamab, is a monoclonal antibody used in a combination therapy for treating adults with relapsed or refractory diffuse […] The post Incyte reveals promising results for Monjuvi trial appeared first on Delaware Business […]